Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease
The company is primarily engaged in addressing unmet medical needs in anemia caused by chronic kidney disease, aiming to enhance patient outcomes through its proprietary treatments and drug candidates. Akebia's research and development efforts are centered around creating therapies that improve the management of renal diseases by promoting better health and quality of life for patients suffering from kidney-related conditions.
Akebia Therapeutics Inc. (NASDAQAKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia
Akebia Therapeutics, Inc. (NASDAQAKBA) is one today’s most active stocks by volume. So far today, approximately 31.95M shares of Akebia Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 4.98M shares.
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000 suffer from end-stage renal disease (ESRD). Of these, nearly 500,000 require dialysis to stay alive. In fact, each year, more people die from this silent killer than from breast or prostate cancer.
San Diego, CA -- (SBWIRE) -- 06/20/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Akebia Therapeutics, Inc..
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQAKBA) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Investors have until May 13, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
San Diego, CA -- (SBWIRE) -- 05/10/2022 -- The Shareholders Foundation announced that a deadline is coming up on May 13, 2022 in the lawsuit filed for certain investors of Akebia Therapeutics, Inc. (NASDAQAKBA).
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQAKBA) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/akba.
San Diego, CA -- (SBWIRE) -- 03/30/2022 -- An investor, who purchased shares of Akebia Therapeutics, Inc. (NASDAQAKBA), filed a lawsuit over alleged violations of Federal Securities Laws by Akebia Therapeutics, Inc.
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQAKBA) and certain of its officers, on behalf of all persons and entities that purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/akba.
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQAKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022 lead plaintiff deadline.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQAKBA) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the “Class Period”). Investors have until May 13, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQAKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2022.
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders who acquired Akebia Therapeutics, Inc. (NASDAQAKBA) common stock in the December 2018 transaction by which Keryx became a wholly owned subsidiary of Akebia. Such shareholders are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/akba.
Investors were all spooked today with Dow plummeting more than 500 points. The primary cause can be attributed to inflation fears, disappointing earnings, and booming bond yields. Tech stocks drove the Dow down with the NASDAQ skidding 2.6 percent and the S&P 500 index falling 1.8 percent. The Dow closed down 1.5 percent. With the market selling off, it’s may very well be time to dive into biotech stocks currently trading at bargain prices. Some of the best value biotech stocks coupled with growth and momentum that needs to make the top of the Biotech Stock list include Brickell Biotech Inc (NASDAQBBI), Intercept Pharmaceuticals Inc. NASDAQ:ICPTNASDAQICPT)(NASDAQ:AKBANASDAQAKBA, uniQure NV (NASDAQ:QURENASDAQ), BioNTech SE (NASDAQ:BNTXBNTX), Seres Therapeutics Inc. (NASDAQMCRB), Marinus Pharmaceuticals Inc. NASDAQ:MRNSNASDAQMRNS)(NASDAQ:AADINASDAQAADI, Cassava Sciences Inc. (NASDAQ:SAVANASDAQ). During the past year, biotech stocks, as represented by the iShares Biotechnology ETF (IBB), have posted a total return of -12.8%, significantly below the Russell 1000's total return of 21.0% as of Jan. 13, 2022. However, 2022 could very well be a turning point for the biotech charts to run up.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Akebia Therapeutics, Inc. (“Akebia” or “the Company”) (NASDAQAKBA) who formerly held shares of Keryx Biopharmaceuticals, Inc. (KERX) for violations of the securities laws.
Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of former Keryx Biopharmaceuticals, Inc. (KERX) shareholders who acquired Akebia Therapeutics, Inc. (NASDAQAKBA) common stock in the December 2018 transaction by which Keryx became a wholly owned subsidiary of Akebia. Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology. At the time of the merger, Akebia's lead product candidate, vadadustat, was an oral therapy in Phase 3 development and expected to become a new standard of care in the treatment of anemia due to chronic kidney disease ("CKD").
